Age and Menopausal Status Affect Osteoprotegerin and Osteocalcin Levels in Women Differently, Irrespective of Thyroid Function

Osteoprotegerin (OPG) and osteocalcin (OC) are essential bone proteins. Recent studies have demonstrated that they are not secreted solely by bone cells; they play roles in the vascular function and energy metabolism, and they are influenced by multiple factors. The aim of the current study was to investigate the influence of menopause and age on OPG and OC in women with different thyroid-stimulating hormone (TSH) levels. Material and Methods We studied 49 women with elevated TSH, 26 with suppressed TSH, and 67 age-matched euthyroid controls. Of them 64 were menstruating and 78 postmenopausal. Body weight, height, waist circumference (WC), body mass index (BMI), serum TSH, free thyroxin (FT4), OPG, and OC were measured. Results Generally, both OPG and OC were higher in the postmenopausal women than in the menstruating subjects (OPG 3.85 ± 1.49 pmol/L vs. 5.84 ± 2.42 pmol/L, P < 0.001; OC 8.84 ± 3.70 ng/dL vs. 12.87 ± 6.45 ng/dL, P < 0.001), and within the two thyroid dysfunction subgroups and the controls (all P < 0.05). OPG correlated with age (postmenopausal rho = 0.57, P < 0.001; premenopausal rho = 0.31, P = 0.015). Among the premenopausal subjects, OPG was higher in those with low TSH than in the controls (P = 0.048). OC correlated negatively with BMI and WC in the postmenopausal group (Spearman rho = –-0.25, P = 0.03 and rho = –-0.42, P < 0.001 respectively). OC was higher in the postmenopausal subjects with low TSH than in those with elevated TSH (P = 0.024), and correlated positively with FT4 (rho = 0.40, P = 0.002) and negatively with TSH (rho = -0.29, P = 0.013). CONCLUSIONS In women, OPG and OC depended differently on age and menopause and, to a lesser extent, on the thyroid function and body composition.

[1]  C. Hsieh,et al.  The relationship between regional abdominal fat distribution and both insulin resistance and subclinical chronic inflammation in non-diabetic adults , 2014, Diabetology & Metabolic Syndrome.

[2]  Merlin C. Thomas,et al.  Osteoprotegerin Is an Independent Predictor of Vascular Events in Finnish Adults With Type 1 Diabetes , 2013, Diabetes Care.

[3]  S. Cummings,et al.  Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON‐PFT, and FREEDOM trials , 2013, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  C. Pepene Serum under-carboxylated osteocalcin levels in women with polycystic ovary syndrome: weight-dependent relationships with endocrine and metabolic traits , 2013, Journal of Ovarian Research.

[5]  M. Emoto,et al.  Undercarboxylated osteocalcin does not correlate with insulin resistance as assessed by euglycemic hyperinsulinemic clamp technique in patients with type 2 diabetes mellitus , 2012, Diabetology & Metabolic Syndrome.

[6]  L. Rasmussen,et al.  No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells , 2012, Molecular and Cellular Endocrinology.

[7]  M. Muñoz-Torres,et al.  Role of serum FSH measurement on bone resorption in postmenopausal women , 2012, Endocrine.

[8]  M. Zaidi,et al.  Thyroid-stimulating hormone induces a Wnt-dependent, feed-forward loop for osteoblastogenesis in embryonic stem cell cultures , 2011, Proceedings of the National Academy of Sciences.

[9]  Soma Sh Abd El Gawad,et al.  Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men , 2011, BMC endocrine disorders.

[10]  S. Yano,et al.  Serum osteocalcin level is positively associated with insulin sensitivity and secretion in patients with type 2 diabetes. , 2011, Bone.

[11]  E. Mathiesen,et al.  Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population – the Tromsø study , 2010, Journal of thrombosis and haemostasis : JTH.

[12]  S. Yano,et al.  Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  D. Mellström,et al.  Plasma Osteocalcin Is Inversely Related to Fat Mass and Plasma Glucose in Elderly Swedish Men , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  U. Gaspard Hyperinsulinaemia, a key factor of the metabolic syndrome in postmenopausal women. , 2009, Maturitas.

[15]  B. Dawson-Hughes,et al.  Association between serum osteocalcin and markers of metabolic phenotype. , 2009, The Journal of clinical endocrinology and metabolism.

[16]  A. Papavassiliou,et al.  A possible role of osteocalcin in the regulation of insulin secretion: human in vivo evidence? , 2008, The Journal of endocrinology.

[17]  S. Khosla,et al.  Osteocalcin expression by circulating endothelial progenitor cells in patients with coronary atherosclerosis. , 2008, Journal of the American College of Cardiology.

[18]  J. Jeon,et al.  Relationship between osteocalcin and glucose metabolism in postmenopausal women. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[19]  T. Pilli,et al.  The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. , 2008, Thyroid : official journal of the American Thyroid Association.

[20]  G. Karsenty,et al.  Osteocalcin differentially regulates β cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice , 2008, Proceedings of the National Academy of Sciences.

[21]  P. Kostenuik,et al.  Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(−/−) Mice , 2008, Circulation.

[22]  Lin-shuang Zhao,et al.  [Changes in plasma concentrations of osteoprotegerin before and after levothyroxine replacement therapy in hypothyroid patients]. , 2007, Zhonghua yi xue za zhi.

[23]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[24]  J. L. San Millán,et al.  Thyroid hormone deficiency and postmenopausal status independently increase serum osteoprotegerin concentrations in women. , 2007, European journal of endocrinology.

[25]  M. Inaba,et al.  Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. , 2005, European journal of endocrinology.

[26]  B. Obermayer-Pietsch,et al.  Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment. , 2003, Thyroid : official journal of the American Thyroid Association.

[27]  S. Erkaya,et al.  Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[28]  L. Hofbauer,et al.  The Role of Receptor Activator of Nuclear Factor-κB Ligand and Osteoprotegerin in the Pathogenesis and Treatment of Metabolic Bone Diseases1 , 2000 .

[29]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[30]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[31]  A. Kung,et al.  Thyroxine suppressive therapy decreases bone mineral density in post‐menopausal women , 1993, Clinical endocrinology.

[32]  J B Lian,et al.  Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. , 1989, Physiological reviews.

[33]  M. Górska,et al.  Interleukin-6 and its considerable role in the pathogenesis of thyrotoxicosis-related disturbances of bone turnover in postmenopausal women. , 2011, Endokrynologia Polska.

[34]  I. Holen,et al.  Pathophysiological roles of osteoprotegerin (OPG). , 2009, European journal of cell biology.

[35]  X. Qiao,et al.  Sex steroids and vascular responses in hypertension and aging. , 2008, Gender medicine.

[36]  Z. Belaya,et al.  Subclinical hyperthyroidism of variable etiology and its influence on bone in postmenopausal women. , 2007, Hormones.